Saxenda for weight loss: separating real results from TikTok hype
Quick answer
The creator is using liraglutide 3.0 mg (Saxenda), a GLP-1 receptor agonist FDA-approved for chronic weight management, prescribed by her primary care physician following prior failed attempts with pharmacotherapy, supervised exercise, and bariatric surgery evaluation. She reports 31 pounds of weight loss over six weeks with intermittent nausea, consistent with the known side effect profile of liraglutide in early treatment phases. Her insurance coverage situation is atypical and should not be used as a reference point for cost expectations.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @shanna_beth actually say?
Shanna shared a six-week Saxenda update, claiming she lost 31 pounds since starting the medication. She got her prescription through her primary care doctor, pays roughly four dollars a month out of pocket because her insurance covers it, and described manageable nausea that varies day to day. She also mentioned eating smaller portions and making herself sick when she tried to eat too much.
To her credit, she gave real context: she tried phentermine, tried working with a personal trainer until she got injured, and was approved for bariatric surgery before deciding to try GLP-1 injections first. That's not a casual dieter reaching for a quick fix. That's someone with a documented weight history working through legitimate options in a reasonable order.
She also apologized to viewers who can't afford Saxenda without coverage, which is a more self-aware disclosure than most influencers bother to make.
Does the science back this up?
The 31-pound figure is the one that deserves scrutiny. It is on the high end of what clinical data would predict, but not impossible given starting weight, water loss, and individual variation.
In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine), participants on liraglutide 3.0 mg lost an average of 8.4 kg (about 18.5 lbs) over 56 weeks, compared to 2.8 kg on placebo. That's a full year, not six weeks. However, early weight loss tends to be faster, and a large portion of initial loss is water weight tied to glycogen depletion and reduced sodium retention from eating less. Someone with a higher starting body weight can lose more in absolute pounds early on.
Thirty-one pounds in six weeks is roughly 5 pounds per week on average. That exceeds what most clinical trials document as average, but averages obscure individual outliers. It is not biologically impossible, especially if she started at a significantly higher weight. What it is, is not typical, and viewers should not use her number as a benchmark for their own expectations.
Her description of nausea as inconsistent and manageable tracks well with the literature. Nausea is the most common side effect of liraglutide, reported in up to 39.3% of participants in SCALE trials, and it tends to peak early and diminish over time as the body adjusts.
What did they get wrong (or right)?
She got the side effect picture mostly right. Nausea that comes and goes, eating smaller portions involuntarily, and feeling sick when overeating are all consistent with how liraglutide works: it slows gastric emptying and acts on appetite-regulating receptors in the brain. She is not fabricating symptoms for content.
What she did not address, and what is worth flagging, is that a 31-pound loss in six weeks should involve a conversation with her doctor about whether that rate is sustainable or whether it signals something worth monitoring. Rapid weight loss can accelerate gallstone formation. The SCALE trials noted cholelithiasis occurred in 2.5% of liraglutide users versus 1.0% on placebo. That is not a reason to stop the medication, but it is a reason to stay in contact with your prescriber, not just TikTok.
She also casually mentioned being prescribed Saxenda by her primary doctor, which is completely legitimate and increasingly common. Primary care physicians can and do prescribe GLP-1 medications for obesity. Nothing problematic there.
What should you actually know?
If you are watching this video and thinking about Saxenda, here is what the data actually says. Average weight loss on liraglutide 3.0 mg at one year is roughly 5 to 8 percent of body weight in most trials, though some individuals lose significantly more. The drug is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition.
Insurance coverage for Saxenda varies dramatically. Many commercial plans cover it; Medicare Part D historically has not, though this is shifting. The list price without insurance runs over 1,300 dollars per month. Shanna's four-dollar copay is genuinely unusual and reflects strong employer-sponsored coverage, not the norm.
A few things to watch for if you are on liraglutide:
- Nausea and vomiting are common early on and usually improve after the first few weeks.
- Gallbladder issues are a documented risk with rapid weight loss on GLP-1 drugs. Report right upper abdominal pain to your doctor.
- Liraglutide carries a boxed warning for thyroid C-cell tumors observed in rodents. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma.
- Weight loss results vary significantly. Do not calibrate your expectations to an influencer's six-week highlight reel.
Shanna's experience is real, but it is one data point from one person. Your weight, your starting dose, your diet, your hormones, and your medical history all shape your outcome differently.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Saxenda for weight loss: separating real results from TikTok hype, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Saxenda for weight loss: separating real results from TikTok hype should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is using liraglutide 3.
FormBlends verdict
The creator is using liraglutide 3.0 mg (Saxenda), a GLP-1 receptor agonist FDA-approved for chronic weight management, prescribed by her primary care physician following prior failed attempts with pharmacotherapy, supervised exercise, and bariatric surgery evaluation. She reports 31 pounds of weight loss over six weeks with intermittent nausea, consistent with the known side effect profile of liraglutide in early treatment phases. Her insurance coverage situation is atypical and should not be used as a reference point for cost expectations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is using liraglutide 3.0 mg (Saxenda), a GLP-1 receptor agonist FDA-approved for chronic weight management, prescribed by her primary care physician following prior failed attempts with pharmacotherapy, supervised exercise, and bariatric surgery evaluation. She reports 31 pounds of weight loss over six weeks with intermittent nausea, consistent with the known side effect profile of liraglutide in early treatment phases. Her insurance coverage situation is atypical and should not be used as a reference point for cost expectations.
- In the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM), average weight loss on liraglutide 3.0 mg was about 18.5 lbs over 56 weeks. A 31-pound loss in 6 weeks is above average and should not set viewer expectations.
- Nausea on liraglutide is real and common, affecting up to 39% of users in clinical trials, but typically decreases after the first several weeks of treatment.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- In the SCALE Obesity trial (Pi-Sunyer et al., 2015, NEJM), average weight loss on liraglutide 3.0 mg was about 18.5 lbs over 56 weeks. A 31-pound loss in 6 weeks is above average and should not set viewer expectations.
- Nausea on liraglutide is real and common, affecting up to 39% of users in clinical trials, but typically decreases after the first several weeks of treatment.
- Saxenda's list price without insurance exceeds 1,300 dollars per month. A four-dollar copay reflects unusually strong insurance coverage, not typical patient cost.
- Rapid weight loss on GLP-1 drugs increases the risk of gallstone formation. The SCALE trials documented cholelithiasis in 2.5% of liraglutide users versus 1.0% on placebo.
- Saxenda carries an FDA boxed warning: it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- Primary care physicians can legally and appropriately prescribe Saxenda for obesity. A specialist referral is not required.
- Early weight loss on GLP-1 medications includes a significant water weight component tied to reduced caloric intake and glycogen depletion, which can inflate short-term numbers.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Shanna_Beth · TikTok creator
123.9K views on this video
Update on #saxenda
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Shanna_Beth, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.